| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5621 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2898 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1761 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1401 | 2021 |
| Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak K Ewer, J Deeks, L Alvarez, G Bryant, S Waller, P Andersen, P Monk, ... The Lancet 361 (9364), 1168-1173, 2003 | 898 | 2003 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 763 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 636 | 2021 |
| Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study S Liebeschuetz, S Bamber, K Ewer, J Deeks, AA Pathan, A Lalvani The Lancet 364 (9452), 2196-2203, 2004 | 549 | 2004 |
| Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells ALN Chapman, M Munkanta, KA Wilkinson, AA Pathan, K Ewer, H Ayles, ... Aids 16 (17), 2285-2293, 2002 | 508 | 2002 |
| Enumeration of T Cells Specific for RD1-Encoded Antigens Suggests a High Prevalence of Latent Mycobacterium tuberculosis Infection in Healthy Urban Indians A Lalvani, P Nagvenkar, Z Udwadia, AA Pathan, KA Wilkinson, JS Shastri, ... The Journal of infectious diseases 183 (3), 469-477, 2001 | 494 | 2001 |
| Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial MS Datoo, MH Natama, A Somé, O Traoré, T Rouamba, D Bellamy, ... The Lancet 397 (10287), 1809-1818, 2021 | 421 | 2021 |
| Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ... Jama 315 (15), 1610-1623, 2016 | 395 | 2016 |
| Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study A Soysal, KA Millington, M Bakir, D Dosanjh, Y Aslan, JJ Deeks, S Efe, ... The Lancet 366 (9495), 1443-1451, 2005 | 381 | 2005 |
| Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation KJ Ewer, GA O’Hara, CJA Duncan, KA Collins, SH Sheehy, ... Nature communications 4 (1), 2836, 2013 | 374 | 2013 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 359 | 2021 |
| Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA− NP+ M1 TK Berthoud, M Hamill, PJ Lillie, L Hwenda, KA Collins, KJ Ewer, A Milicic, ... Clinical infectious diseases 52 (1), 1-7, 2011 | 356 | 2011 |
| Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species S Colloca, E Barnes, A Folgori, V Ammendola, S Capone, A Cirillo, ... Science translational medicine 4 (115), 115ra2-115ra2, 2012 | 354 | 2012 |
| A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA K Ewer, T Rampling, N Venkatraman, G Bowyer, D Wright, T Lambe, ... New England Journal of Medicine 374 (17), 1635-1646, 2016 | 315 | 2016 |
| Viral vectors as vaccine platforms: deployment in sight CS Rollier, A Reyes-Sandoval, MG Cottingham, K Ewer, AVS Hill Current opinion in immunology 23 (3), 377-382, 2011 | 296 | 2011 |
| Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis K Ewer, KA Millington, JJ Deeks, L Alvarez, G Bryant, A Lalvani American journal of respiratory and critical care medicine 174 (7), 831-839, 2006 | 285 | 2006 |
Sarah C GilbertProfessor of Vaccinology, Pandemic Sciences Institute, Oxford UniversityVerified email at ndm.ox.ac.uk